MA46146A1 - Insuline a action prolongée et utilisation associée - Google Patents

Insuline a action prolongée et utilisation associée

Info

Publication number
MA46146A1
MA46146A1 MA46146A MA46146A MA46146A1 MA 46146 A1 MA46146 A1 MA 46146A1 MA 46146 A MA46146 A MA 46146A MA 46146 A MA46146 A MA 46146A MA 46146 A1 MA46146 A1 MA 46146A1
Authority
MA
Morocco
Prior art keywords
long
insulin
acting insulin
associated use
acting
Prior art date
Application number
MA46146A
Other languages
English (en)
Inventor
Sang Youn Hwang
Sung Youb Jung
Euh Lim Oh
Sung Hee Park
Hyun Uk Kim
Chang Ki Lim
Se Chang Kwon
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of MA46146A1 publication Critical patent/MA46146A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne : un analogue de l'insuline dans lequel la force de liaison au récepteur de l'insuline est réduite afin d'augmenter la demi-vie de l'insuline dans le sang ; une insuline à action prolongée utilisant celui-ci ; un complexe ; et un procédé de préparation de l'insuline à action prolongée.
MA46146A 2014-01-20 2015-01-20 Insuline a action prolongée et utilisation associée MA46146A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20140006938 2014-01-20
PCT/KR2015/000576 WO2015108398A1 (fr) 2014-01-20 2015-01-20 Insuline à action prolongée et utilisation associée

Publications (1)

Publication Number Publication Date
MA46146A1 true MA46146A1 (fr) 2020-12-31

Family

ID=53543214

Family Applications (3)

Application Number Title Priority Date Filing Date
MA46146A MA46146A1 (fr) 2014-01-20 2015-01-20 Insuline a action prolongée et utilisation associée
MA39301A MA39301A1 (fr) 2014-01-20 2015-01-20 Insuline à action prolongée et utilisation associée
MA43289A MA43289B1 (fr) 2014-01-20 2015-01-20 Insuline à action prolongée et utilisation associée

Family Applications After (2)

Application Number Title Priority Date Filing Date
MA39301A MA39301A1 (fr) 2014-01-20 2015-01-20 Insuline à action prolongée et utilisation associée
MA43289A MA43289B1 (fr) 2014-01-20 2015-01-20 Insuline à action prolongée et utilisation associée

Country Status (22)

Country Link
US (1) US10253082B2 (fr)
EP (1) EP3098235A4 (fr)
JP (1) JP2017505141A (fr)
KR (1) KR102406654B1 (fr)
CN (2) CN116987172A (fr)
AU (1) AU2015206890B2 (fr)
BR (1) BR112016016578A2 (fr)
CA (1) CA2937168A1 (fr)
CL (1) CL2016001844A1 (fr)
CR (1) CR20160376A (fr)
DO (1) DOP2016000176A (fr)
EA (1) EA201691374A1 (fr)
EC (1) ECSP16068524A (fr)
IL (1) IL246782B (fr)
MA (3) MA46146A1 (fr)
MX (1) MX369656B (fr)
MY (1) MY186251A (fr)
PE (1) PE20161153A1 (fr)
PH (1) PH12016501414B1 (fr)
SG (1) SG11201605680PA (fr)
WO (1) WO2015108398A1 (fr)
ZA (1) ZA201605626B (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2016009465A (es) 2014-01-20 2016-12-02 Cleave Biosciences Inc Pirimidinas fusionadas como inhibidores del complejo p97.
EA036714B1 (ru) 2014-11-21 2020-12-10 Мерк Шарп И Доум Корп. Частичные агонисты инсулинового рецептора
AR105616A1 (es) 2015-05-07 2017-10-25 Lilly Co Eli Proteínas de fusión
UY36870A (es) 2015-08-28 2017-03-31 Hanmi Pharm Ind Co Ltd Análogos de insulina novedosos
WO2017052305A1 (fr) * 2015-09-24 2017-03-30 Hanmi Pharm. Co., Ltd. Procédé de production d'insuline
TWI774694B (zh) * 2016-09-23 2022-08-21 南韓商韓美藥品股份有限公司 具有降低對胰島素受體之親和力之胰島素類似物及其用途
CN110545849A (zh) 2017-02-03 2019-12-06 韩美药品株式会社 具有增加的持续性的生理活性物质的缀合物及其应用
CA3054899A1 (fr) * 2017-03-23 2018-09-27 Hanmi Pharm. Co., Ltd. Complexe d'analogue a l'insuline a affinite reduite pour le recepteur de l'insuline et son utilisation
CN111406073A (zh) * 2017-09-29 2020-07-10 韩美药品株式会社 具有提高功效的持久性蛋白质缀合物
KR102666154B1 (ko) * 2018-08-08 2024-05-20 주식회사 대웅제약 지속형 인슐린 아날로그 및 그 복합체
KR102646845B1 (ko) 2018-08-08 2024-03-14 주식회사 대웅제약 클로스트리파인을 이용한 지속형 인슐린 아날로그 복합체의 활성형 제조방법
TW202039438A (zh) 2018-12-11 2020-11-01 法商賽諾菲公司 胰島素接合物
JP2022542301A (ja) * 2019-07-31 2022-09-30 イーライ リリー アンド カンパニー リラキシン類似体およびその使用方法
KR102545250B1 (ko) * 2020-03-31 2023-06-21 한미약품 주식회사 신규한 면역 활성 인터루킨 2 아날로그

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5175145A (en) 1988-08-26 1992-12-29 Amylin Pharmaceuticals, Inc. Treatment of diabetes mellitus with amylin agonists
US5422339A (en) * 1991-03-19 1995-06-06 Joslin Diabetes Center, Inc. Peptides having insulin autoantibody but not insulin receptor binding capacity
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
CA2249195A1 (fr) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Domaines analogues a l'immunoglobuline a demi-vies prolongees
IL143866A0 (en) 1999-01-06 2002-04-21 Genentech Inc Insulin-like growth factor (igf) i mutant variants
AR036711A1 (es) 2001-10-05 2004-09-29 Bayer Corp Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor del glucagon y sus metodos de uso farmacologico
DE10227232A1 (de) 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
US20050176108A1 (en) * 2003-03-13 2005-08-11 Young-Min Kim Physiologically active polypeptide conjugate having prolonged in vivo half-life
KR20050121748A (ko) 2003-04-29 2005-12-27 일라이 릴리 앤드 캄파니 연장된 시간 작용을 갖는 인슐린 유사체
DK1648933T3 (da) 2003-07-25 2009-09-07 Conjuchem Biotechnologies Inc Langvarige insulinderivater og fremgangsm der
PT2256134E (pt) 2003-11-13 2014-03-05 Hanmi Science Co Ltd Fragmento fc de igg para um veículo de fármaco e método para a preparação do mesmo
JP5366546B2 (ja) 2005-08-16 2013-12-11 ノボ・ノルデイスク・エー／エス 成熟インスリンポリペプチドの作製方法
EP2049149B1 (fr) * 2006-07-31 2015-04-15 Novo Nordisk A/S Insulines pegylées à extensions
WO2008049711A1 (fr) * 2006-10-27 2008-05-02 Novo Nordisk A/S Insuline à peptide ajouté
US7790677B2 (en) 2006-12-13 2010-09-07 Elona Biotechnologies Insulin production methods and pro-insulin constructs
JP2008169195A (ja) 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd キャリア物質を用いたインスリン分泌ペプチド薬物結合体
EP2017288A1 (fr) 2007-07-16 2009-01-21 Novo Nordisk A/S Analogues de l'insuline pégylés, stabilisés à la protéase
JP5688969B2 (ja) * 2007-07-16 2015-03-25 ノボ・ノルデイスク・エー／エス プロテアーゼに対して安定しているペグ化インスリンアナログ
JP2009019027A (ja) 2007-07-16 2009-01-29 Hanmi Pharmaceutical Co Ltd アミノ末端のアミノ酸が変異したインスリン分泌ペプチド誘導体
US9150633B2 (en) 2007-08-15 2015-10-06 Novo Nordisk A/S Insulin analogues with an acyl and alkylene glycol moiety
JP5241849B2 (ja) 2007-11-16 2013-07-17 ノボ・ノルデイスク・エー／エス インスリン及びインスリン分泌性ペプチドを含む薬学的組成物
DE102008025008A1 (de) 2008-05-24 2009-11-26 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
NZ586590A (en) 2008-01-09 2012-06-29 Sanofi Aventis Deutschland Insulin analogues or derivatives having an extremely delayed time-action profile
KR20100111683A (ko) 2008-01-09 2010-10-15 사노피-아벤티스 도이칠란트 게엠베하 극히 지연된 시간-작용 프로필을 갖는 신규 인슐린 유도체
DE102008003568A1 (de) 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
WO2009112583A2 (fr) * 2008-03-14 2009-09-17 Novo Nordisk A/S Analogues de l’insuline stabilisés une protéase
MX2010009850A (es) 2008-03-18 2010-09-30 Novo Nordisk As Analogos de insulina acilados y etabilizados contra proteasas.
WO2009129250A2 (fr) 2008-04-14 2009-10-22 Case Western Reserve University Analogues de l'insuline à prendre au moment des repas de stabilité améliorée
PT3228320T (pt) 2008-10-17 2020-03-26 Sanofi Aventis Deutschland Combinação de uma insulina e de um agonista do glp-1
AU2009335715B2 (en) 2008-12-19 2016-09-15 Indiana University Research And Technology Corporation Amide-based insulin prodrugs
EP2376520B1 (fr) 2008-12-19 2014-02-12 Indiana University Research&Technology Corporation Analogues d'insuline
MX2011010151A (es) 2009-03-27 2011-12-14 Glaxo Group Ltd Fusiones y conjugados de farmaco.
US20120184488A1 (en) * 2009-09-01 2012-07-19 Case Western Reserve University Insulin analogues of enhanced receptor-binding specificity
KR101058209B1 (ko) 2009-12-30 2011-08-22 전자부품연구원 Ｏｆｄｍ 방식의 디지털 방송 시스템의 빠른 동기 방법
AR081066A1 (es) 2010-04-02 2012-06-06 Hanmi Holdings Co Ltd Conjugado de insulina donde se usa un fragmento de inmunoglobulina
KR101324828B1 (ko) 2010-06-08 2013-11-01 한미사이언스 주식회사 면역글로불린 단편을 이용한 단쇄 인슐린 아날로그 약물 결합체
KR101330868B1 (ko) * 2010-06-08 2013-11-18 한미사이언스 주식회사 면역글로불린 단편을 이용한 인슐린 유도체 약물 결합체
US8940860B2 (en) * 2010-06-16 2015-01-27 Indiana University Research And Technology Corporation Single-chain insulin agonists exhibiting high activity at the insulin receptor
KR101382593B1 (ko) 2010-07-21 2014-04-10 한미사이언스 주식회사 신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물
AU2011282988A1 (en) 2010-07-28 2013-01-31 Smartcells, Inc. Recombinantly expressed insulin polypeptides and uses thereof
EA201390796A1 (ru) 2011-01-20 2014-07-30 Зилэнд Фарма А/С Применение ацилированного аналога глюкагона
CN103635602B (zh) 2011-03-02 2016-08-31 欧瑞康表面解决方案股份公司，普费菲孔 用于在润滑条件下通过摩擦应用改进磨损和摩擦性能的用含金属碳层涂布的滑动组件
CN102675452B (zh) * 2011-03-17 2015-09-16 重庆富进生物医药有限公司 具持续降血糖和受体高结合的人胰岛素及类似物的偶联物
RU2578641C2 (ru) 2011-05-03 2016-03-27 Тейджин Арамид Б.В. Пуленепробиваемая панель
BR112013030933A2 (pt) 2011-06-02 2018-04-24 Prolor Biotech Inc agonistas do receptor de glp-1/glucágon de ação prolongada
UA113626C2 (xx) 2011-06-02 2017-02-27 Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії
PE20140765A1 (es) 2011-06-10 2014-06-14 Hanmi Science Co Ltd Derivados de oxintomodulina novedosos y composicion farmaceutica para tratar la obesidad que comprende los mismos
ES2710356T3 (es) 2011-06-17 2019-04-24 Hanmi Science Co Ltd Conjugado que comprende oxintomodulina y un fragmento de inmunoglobulina, y uso del mismo
WO2013089463A1 (fr) 2011-12-16 2013-06-20 Lg Innotek Co., Ltd. Procédé de dépôt de carbure de silicium et tranche épitaxiale de carbure de silicium
JP2015507916A (ja) 2012-01-20 2015-03-16 ケース ウェスタン リザーブ ユニバーシティＣａｓｅ Ｗｅｓｔｅｒｎｒｅｓｅｒｖｅ Ｕｎｉｖｅｒｓｉｔｙ グルタミン酸安定化インスリン類似体
KR101665009B1 (ko) 2012-03-09 2016-10-11 한미사이언스 주식회사 비알콜성 지방간 질환의 예방 또는 치료용 약학적 조성물
AR094821A1 (es) 2012-07-25 2015-09-02 Hanmi Pharm Ind Co Ltd Formulación líquida de un conjugado de péptido insulinotrópico de acción prolongada
AR092862A1 (es) 2012-07-25 2015-05-06 Hanmi Pharm Ind Co Ltd Formulacion liquida de insulina de accion prolongada y un peptido insulinotropico y metodo de preparacion
AR091902A1 (es) 2012-07-25 2015-03-11 Hanmi Pharm Ind Co Ltd Formulacion liquida de un conjugado de insulina de accion prolongada
KR101968344B1 (ko) 2012-07-25 2019-04-12 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물
AR092873A1 (es) 2012-09-26 2015-05-06 Cadila Healthcare Ltd Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon
PH12018501454A1 (en) 2012-11-06 2020-02-17 Hanmi Pharm Ind Co Ltd Liquid formulation of protein conjugate comprising the oxyntomodulin and an immunoglubin fragment
PE20151409A1 (es) 2013-02-26 2015-10-07 Hanmi Pharm Ind Co Ltd Analogo de insulina novedoso y su uso
AR100639A1 (es) 2014-05-29 2016-10-19 Hanmi Pharm Ind Co Ltd Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada
KR101676542B1 (ko) 2014-12-30 2016-11-16 건국대학교 산학협력단 프로인슐린의 면역학적 용도

Also Published As

Publication number Publication date
MX2016009434A (es) 2017-01-18
CN105916877A (zh) 2016-08-31
CL2016001844A1 (es) 2017-01-06
IL246782B (en) 2020-01-30
DOP2016000176A (es) 2017-02-15
PE20161153A1 (es) 2016-10-27
MA39301A1 (fr) 2018-01-31
EP3098235A1 (fr) 2016-11-30
AU2015206890A1 (en) 2016-08-04
ZA201605626B (en) 2017-11-29
US10253082B2 (en) 2019-04-09
CA2937168A1 (fr) 2015-07-23
PH12016501414A1 (en) 2016-09-14
ECSP16068524A (es) 2018-11-30
EA201691374A1 (ru) 2016-12-30
IL246782A0 (en) 2016-08-31
US20170101455A1 (en) 2017-04-13
CR20160376A (es) 2016-10-07
EP3098235A4 (fr) 2017-10-18
MX369656B (es) 2019-11-15
KR20150087130A (ko) 2015-07-29
PH12016501414B1 (en) 2016-09-14
BR112016016578A2 (pt) 2017-10-03
CN116987172A (zh) 2023-11-03
SG11201605680PA (en) 2016-09-29
KR102406654B1 (ko) 2022-06-10
JP2017505141A (ja) 2017-02-16
MA43289B1 (fr) 2019-12-31
MY186251A (en) 2021-06-30
AU2015206890B2 (en) 2019-05-23
WO2015108398A1 (fr) 2015-07-23

Similar Documents

Publication Publication Date Title
MA46146A1 (fr) Insuline a action prolongée et utilisation associée
CL2016003075A1 (es) Composición para tratar diabetes, que contiene un conjugado de análogo de insulina de acción prolongada y un conjugado de péptido insulinotrópico de acción prolongada
EA201590058A1 (ru) Аналоги глюкагона
EA201991696A1 (ru) Т-клеточные рецепторы, связывающиеся с ny-eso-1, и способы их применения
PH12017500402A1 (en) Anti-glucagon antibodies and uses thereof
MX2016016868A (es) Derivados de exendina-4 como agonistas selectivos del receptor de glucagon.
CO6311108A2 (es) Analogos de insulina en los cuales el extremo de la cadena b consiste en un residuo aminoácido, el residuo de aminoácido n-terminal de la cadena a de la insulina es un residuo lisina o arginina, la posición a8 del aminoácido está ocupada por un resid
MX2017014822A (es) Composiciones y métodos para la reprogramación del tcr con proteínas de fusión.
EA201791117A1 (ru) Частичные агонисты инсулинового рецептора
SA518400491B1 (ar) نظير إنسولين جديد واستخدامه
BR112016023948A2 (pt) proteínas fc multiméricas
MX2016010951A (es) Proteinas de fc multimericas.
DK3294768T3 (da) T-celle-rekrutterende polypeptider baseret på tcr-alfa/beta-reaktivitet
EA201890584A1 (ru) Новые аналоги инсулина и их применение
PE20151871A1 (es) Anticuerpos de receptor anti-glucagon y metodos de uso de los mismos
MX2016013323A (es) Uso medico de compuestos de artemisinina y agonistas de gefirina.
MX366636B (es) Nuevo derivado de un análogo de insulina.
CO2022004757A2 (es) Proteínas que se unen a nkg2d, cd16 y flt3
BR112019010128A2 (pt) proteínas de ligação a antígeno anti-gitr e métodos de uso das mesmas
DK3313816T3 (da) Metabolisk robuste analoger af cyp-eicosanoider til behandling af hjertesygdom
TWD166474S (zh) 手錶
TWD179291S (zh) 座標輸入器之部分
EA201690766A1 (ru) Растворимый fc-гамма рецептор для лечения аутоиммунных буллезных заболеваний
TWD175451S (zh) 錶帶之連接件
Natarajan Modeling performance of serial and parallel sections of multi-threaded programs in many-core era| Theses. fr